Recombinant human neuregulin-1β is protective against radiation-induced myocardial cell injury

Zhou,Qiang; Hu,Wenbing; Fei,Xinxiong; Huang,Xuqun; Chen,Xi; Zhao,Deqing; Huang,Jun; Jiang,Lan; Wang,Gangsheng

doi:10.3892/mmr.2016.5207

Recombinant human neuregulin-1β is protective against radiation-induced myocardial cell injury

Authors:
- Qiang Zhou
- Wenbing Hu
- Xinxiong Fei
- Xuqun Huang
- Xi Chen
- Deqing Zhao
- Jun Huang
- Lan Jiang
- Gangsheng Wang
View Affiliations

Affiliations: Department of Medical Oncology, Huangshi Central Hospital, Huangshi, Hubei 435000, P.R. China
Published online on: May 4, 2016 https://doi.org/10.3892/mmr.2016.5207
Pages: 325-330

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the role of recombinant human neuregulin-1β (rhNRG-1β) in the repair of the radiation-induced damage of myocardial cells and the underlying mechanism. Rats were divided into the radiotherapy alone group, the rhNRG-1β group (radiotherapy with rhNRG‑1β treatment) and the Herceptin group (radiotherapy with Herceptin treatment), and their myocardial cells were analyzed. The morphology of the myocardial cells was observed under an optical microscope, and the expression of γ‑H2AX and p53 was analyzed using immunohistochemistry and western blot analysis. Damage to the myocardial cells was identified in the three groups following radiation treatment, which was identified by cell swelling and altered morphology. The integrated optical density values of γ‑H2AX in the radiotherapy alone, rhNRG‑1β and Herceptin groups were 50.96±5.548, 27.63±10.61 and 76.12±2.084, respectively. The OD of the radiotherapy alone group was significantly higher than that of the rhNRG‑1β treated group (P<0.0001), and the value of the Herceptin group was significantly higher than that of the radiotherapy alone group (P<0.0001). The p53 level in the rhNRG‑1β group was less than that of the radiotherapy alone group (P<0.001), and was higher in the Herceptin group compared with the radiotherapy alone group (P<0.0001). Thus, rhNRG‑1β can ameliorate radiotherapy-induced myocardial cell injury, predominantly by enhancing myocardial cell DNA repair, inhibiting cell apoptosis and improving myocardial function. The results of this study in myocardial cells suggest that patients with thoracic cancer may benefit from treatment with rhNRG‑1β for the repair of the radiation-induced damage of myocardial cells.

View Figures

View References

1	Friedlander AH, Sung EC and Child JS: Radiation-induced heart disease after Hodgkin's disease and breast cancer treatment: Dental implications. J Am Dent Assoc. 134:1615–1620. 2003. View Article : Google Scholar
2	Rutqvist LE, Rose C and Cavallin-Stahl E: A systematic overview of radiation therapy effects in breast cancer. Acta Oncol. 42:532–545. 2003. View Article : Google Scholar : PubMed/NCBI
3	Rutqvist LE, Lax I, Fornander T and Johansson H: Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys. 22:887–896. 1992. View Article : Google Scholar : PubMed/NCBI
4	Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A, Hoskin PJ, Lister A, Radford JA, Rohatiner AZ and Linch DC: Myocardial infarction mortality risk after treatment for Hodgkin disease: A collaborative British cohort study. J Natl Cancer Inst. 99:206–214. 2007. View Article : Google Scholar : PubMed/NCBI
5	Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, et al: Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 368:987–998. 2013. View Article : Google Scholar : PubMed/NCBI
6	Ismaili N, Elmajjaoui S, Tahri A, Benjaafar N, Errihani H and Belbaraka R: Trastuzumab in early breast cancer. Presse Med. 42:1069–1080. 2013.In French. View Article : Google Scholar : PubMed/NCBI
7	Tukenova M, Guibout C, Oberlin O, Doyon F, Mousannif A, Haddy N, Guérin S, Pacquement H, Aouba A, Hawkins M, et al: Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol. 28:1308–1315. 2010. View Article : Google Scholar : PubMed/NCBI
8	Højris I, Overgaard M, Christensen JJ and Overgaard J: Morbidity and mortality of ischaemic heart disease in high-risk breast-cancer patients after adjuvant postmastectomy systemic treatment with or without radiotherapy: Analysis of DBCG 82b and 82c randomised trials. Radiotherapy Committee of the danish breast cancer cooperative group. Lancet. 354:1425–1430. 1999. View Article : Google Scholar
9	Seemann I, Gabriels K, Visser NL, Hoving S, te Poele JA, Pol JF, Gijbels MJ, Janssen BJ, van Leeuwen FW, Daemen MJ, et al: Irradiation induced modest changes in murine cardiac function despite progressive structural damage to the myocardium and microvasculature. Radiother Oncol. 103:143–150. 2012. View Article : Google Scholar
10	Azimzadeh O, Sievert W, Sarioglu H, Merl-Pham J, Yentrapalli R, Bakshi MV, Janik D, Ueffing M, Atkinson MJ, Multhoff G and Tapio S: Integrative proteomics and targeted transcriptomics analyses in cardiac endothelial cells unravel mechanisms of long-term radiation-induced vascular dysfunction. J Proteome Res. 14:1203–1219. 2015. View Article : Google Scholar : PubMed/NCBI
11	Sanchez-Soria P and Camenisch TD: ErbB signaling in cardiac development and disease. Semin Cell Dev Biol. 21:929–935. 2010. View Article : Google Scholar : PubMed/NCBI
12	Hardenbergh PH, Munley MT, Bentel GC, Kedem R, Borges-Neto S, Hollis D, Prosnitz LR and Marks LB: Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: Preliminary results. Int J Radiat Oncol Biol Phys. 49:1023–1028. 2001. View Article : Google Scholar : PubMed/NCBI
13	Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, Hollis D, Lind P, Tisch A, Wong TZ and Borges-Neto S: The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 63:214–23. 2005. View Article : Google Scholar : PubMed/NCBI
14	Sawyer DB and Caggiano A: Neuregulin-1β for the treatment of systolic heart failure. J Mol Cell Cardiol. 51:501–505. 2011. View Article : Google Scholar : PubMed/NCBI
15	Gui C, Zhu L, Hu M, Lei L and Long Q: Neuregulin-1/ErbB signaling is impaired in the rat model of diabetic cardiomyopathy. Cardiovasc Pathol. 21:414–420. 2012. View Article : Google Scholar : PubMed/NCBI
16	Chen C, Heusch A, Donner B, Janssen G, Gobel U and Schmidt KG: Present risk of anthracycline or radiation-induced cardiac sequelae following therapy of malignancies in children and adolescents. Klin Padiatr. 221:162–166. 2009. View Article : Google Scholar : PubMed/NCBI
17	Boulay G and Debaene B: Acute cardiogenic postoperative edema after doxorubicin (adriamycin) chemotherapy. Ann Fr Anesth Reanim. 17:43–46. 1998.In French. View Article : Google Scholar
18	Munk M, Memon AA, Goetze JP, Nielsen LB, Nexo E and Sorensen BS: Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and cultured cardiomyocytes. PloS One. 7:e402432012. View Article : Google Scholar : PubMed/NCBI
19	Haas J, Frese KS, Park YJ, Keller A, Vogel B, Lindroth AM, Weichenhan D, Franke J, Fischer S, Bauer A, et al: Alterations in cardiac DNA methylation in human dilated cardiomyopathy. EMBO Mol Med. 5:413–429. 2013. View Article : Google Scholar : PubMed/NCBI
20	Hernández L, Terradas M, Martín M, Tusell L and Genescà A: Highly sensitive automated method for DNA damage assessment: Gamma-H2AX foci counting and cell cycle sorting. Int J Mol Sci. 14:15810–15826. 2013. View Article : Google Scholar : PubMed/NCBI
21	Gordon LI, Burke MA, Singh AT, Prachand S, Lieberman ED, Sun L, Naik TJ, Prasad SV and Ardehali H: Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways. J Biol Chem. 284:2080–2087. 2009. View Article : Google Scholar :
22	Dienstmann R, Markman B and Tabernero J: Application of monoclonal antibodies as cancer therapy in solid tumors. Curr Clin Pharmacol. 7:137–145. 2012. View Article : Google Scholar : PubMed/NCBI
23	Marín A, Martín M, Linan O, Alvarenga F, Lopez M, Fernandez L, Buchser D and Cerezo L: Bystander effects and radiotherapy. Rep Pract Oncol Radiother. 20:12–21. 2014. View Article : Google Scholar : PubMed/NCBI
24	Ahmed FE: Molecular markers that predict response to colon cancer therapy. Expert Rev Mol Diagn. 5:353–375. 2005. View Article : Google Scholar : PubMed/NCBI
25	Fukazawa R, Miller TA, Kuramochi Y, Frantz S, Kim YD, Marchionni MA, Kelly RA and Sawyer DB: Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J Mol Cell Cardiol. 35:1473–1479. 2003. View Article : Google Scholar : PubMed/NCBI
26	Jiao S, Liu B, Gao A, Ye M, Jia X, Zhang F, Liu H, Shi X and Huang C: Benzo (a)pyrene-caused increased G1-S transition requires the activation of c-Jun through p53-dependent PI-3K/Akt/ERK pathway in human embryo lung fibroblasts. Toxicol Lett. 178:167–175. 2008. View Article : Google Scholar : PubMed/NCBI
27	Yentrapalli R, Azimzadeh O, Barjaktarovic Z, Sarioglu H, Wojcik A, Harms-Ringdahl M, Atkinson MJ, Haghdoost S and Tapio S: Quantitative proteomic analysis reveals induction of premature senescence in human umbilical vein endothelial cells exposed to chronic low-dose rate gamma radiation. Proteomics. 13:1096–1107. 2013. View Article : Google Scholar : PubMed/NCBI
28	Yentrapalli R, Azimzadeh O, Sriharshan A, Malinowsky K, Merl J, Wojcik A, Harms-Ringdahl M, Atkinson MJ, Becker KF, Haghdoost S and Tapio S: The PI3K/Akt/mTOR pathway is implicated in the premature senescence of primary human endothelial cells exposed to chronic radiation. PloS One. 8:e700242013. View Article : Google Scholar : PubMed/NCBI
29	Rana MK and Worthylake RA: Novel mechanism for negatively regulating Rho-kinase (ROCK) signaling through Coronin1B protein in neuregulin 1 (NRG-1)-induced tumor cell motility. J Biol Chem. 287:21836–21845. 2012. View Article : Google Scholar : PubMed/NCBI
30	Chua YL, Ito Y, Pole JC, Newman S, Chin SF, Stein RC, Ellis IO, Caldas C, O'Hare MJ, Murrell A and Edwards PA: The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. Oncogene. 28:4041–4052. 2009. View Article : Google Scholar : PubMed/NCBI
31	Naderi A, Teschendorff AE, Barbosa-Morais NL, Pinder SE, Green AR, Powe DG, Robertson JF, Aparicio S, Ellis IO, Brenton JD and Caldas C: A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 26:1507–1516. 2007. View Article : Google Scholar